Potential contribution of monounsaturated fatty acids to cardiovascular risk in chronic kidney disease

Adriana Mika1,2, Małgorzata Sikorska-Wiśniewska3, Sylwia Małgorzewicz3,4, Piotr Stepnowski1, Alicja Dębska-Ślizień3, Tomasz Śledziński2, Michał Chmielewski3

1 Department of Environmental Analysis, Faculty of Chemistry, University of Gdańsk, Gdańsk, Poland
2 Department of Pharmaceutical Biochemistry, Faculty of Pharmacy, Medical University of Gdańsk, Gdańsk, Poland
3 Department of Nephrology, Transplantology and Internal Medicine, Faculty of Medicine, Medical University of Gdańsk, Gdańsk, Poland
4 Department of Clinical Nutrition, Faculty of Health Sciences, Medical University of Gdańsk, Gdańsk, Poland

Correspondence to: Tomasz Śledziński, PhD, Department of Pharmaceutical Biochemistry, Faculty of Pharmacy, Medical University of Gdańsk, ul. Dębinki 1, 80-211 Gdańsk, Poland, phone: +48 58 349 14 79, email: tsledz@gumed.edu.pl
Received: September 25, 2018.
Revision accepted: November 9, 2018.
Published online: November 20, 2018.
Conflict of interest: none declared.
Pol Arch Intern Med. 2018;128 (12): 755-763
doi:10.20452/pamw.4376
Copyright by Medycyna Praktyczna, Kraków 2018

ABSTRACT

INTRODUCTION Patients with chronic kidney disease (CKD) are particularly susceptible to cardiovascular disease (CVD). Increased synthesis of endogenous monounsaturated fatty acids (MUFAs) by stearoyl-CoA desaturase-1 (SCD1) might predispose to cardiovascular complications.

OBJECTIVES The aim of this study was to examine the serum MUFA content in patients at subsequent stages of CKD, and to evaluate associations between MUFA content and SCD1 activity, patients’ diet, and cardiovascular risk.

PATIENTS AND METHODS Serum fatty acid composition was evaluated in 177 patients with subsequent stages of CKD (1–2, 3a, 3b, 4–5, hemodialysis, peritoneal dialysis, and after kidney transplantation), and in 30 healthy controls. Gas chromatography–mass spectrometry was used for the measurement.

RESULTS Serum MUFA content was shown to increase with subsequent stages of CKD and to be correlated with various risk factors of CVD, including serum triacylglycerols, HDL cholesterol ($P <0.01$), and high-sensitivity C-reactive protein ($P <0.05$). Moreover, also the prevalence of CVD was shown to increase with CKD progression. Estimated SCD1 activity was associated with serum MUFA content ($P <0.01$), but no association was found between dietary MUFA intake and serum MUFA levels.

CONCLUSIONS Our results indicate that the elevation of serum MUFA levels in CKD patients may contribute to an increased risk of CVD during CKD progression, mainly due to increased endogenous MUFA synthesis by SCD1.

INTRODUCTION During the course of chronic kidney disease (CKD), patients are affected by progressive dyslipidemia, which is mainly manifested by elevated concentrations of triacylglycerols (TAGs). Dyslipidemia is a considerable risk factor for cardiovascular disease (CVD) and might affect mortality among CKD patients. Similarly, alterations in renal lipid deposition and metabolism might play an important role in kidney injury. However, lipid disorders at particular stages of the disease progress have not been studied in detail. In CKD patients, the major cardiovascular complication is heart failure, and its occurrence increases with kidney disease progression. Other CVD risk factors in the course of CKD are low concentrations of high-density lipoprotein cholesterol (HDL-C), and low-grade persistent inflammation. These factors promote atherosclerosis and might contribute to the high cardiovascular mortality rate in CKD patients.

The association between CKD and cardiovascular risk is well established. However, the exact contribution of dyslipidemia to CVD in CKD patients remains unclear, and little is known about fatty acid disorders in this population. Recently, we reported disorders of serum omega-3 polyunsaturated fatty acid (PUFA) composition in dialysis patients. However, the main compounds of
TAG are monounsaturated fatty acids (MUFAs), and thus their level may be associated with hypertriglyceridemia observed in CKD. Fatty acid composition of TAG is tightly controlled at a cellular level. Yet, during the disease progression, alterations of fatty acid metabolism and composition might occur, leading to a cascade of adverse events in the body.

In contrast to PUFAs, MUFAs do not belong to essential fatty acids, as they can be synthesized by an endogenous enzyme, stearoyl-coenzyme A desaturase-1 (SCD1). In some countries, consumption of MUFAs accounts for at least one-third of the total fatty acid intake. The main sources of exogenous MUFAs are vegetable oils, high fat fruits such as olives and avocado, red meat, milk products, and nuts. Plant oils, which are rich in MUFAs, have similar beneficial properties to fish oils, which are rich in PUFAs, and might have a beneficial effect on CVD risk reduction in the general population. However, other authors suggested that dietary MUFAs do not provide cardioprotection. By contrast, increased endogenous MUFAs synthesis by SCD1 is associated with metabolic diseases, and increased SCD1 activity has been proposed to be a marker of CVD risk.

Moreover, we observed positive associations between the presence of inflammation in these patients, and serum MUFA levels. This prompted us to determine the significance of serum MUFA content, dietary MUFA intake, and endogenous MUFA synthesis in CKD patients.

In the present study, we investigated serum MUFA levels in patients at subsequent stages of CKD, as well as the potential significance of MUFA for cardiovascular risk during CKD progression. Moreover, we attempted to clarify the major mechanisms that could lead to MUFA disturbances in CKD, by estimating the SCD1 activity and patients’ dietary intake.

**PATIENTS AND METHODS**

**Study cohort**

The study cohort included 207 participants: 40 patients with CKD stage 1–2; 24 patients with CKD stage 3a; 24 patients with CKD stage 3b; 19 patients with CKD stage 4–5; 24 patients on hemodialysis (HD); 22 patients on peritoneal dialysis (PD); 24 kidney transplant (Tx) recipients; and 30 controls matched for age and sex and without any kidney disease. Subjects were recruited from among patients of general medicine clinics. The inclusion criteria for the study group were as follows: age between 18 and 70 years, diagnosed CKD, and consent to participate in the study. Data on comorbidities and the possible use of lipid-lowering drugs were collected. The study conformed to the principles of the Declaration of Helsinki. All experimental protocols of this study were approved by the Local Bioethics Committee at the Medical University of Gdańsk (protocol no. NKEBN/614/2013–2014), and informed consent was obtained from all patients and healthy volunteers before enrollment. All laboratory tests were carried out at the Central Clinical Laboratory of the Medical University of Gdańsk.

**Dietary questionnaire**

Dietary habits were investigated with the use of the Food Frequency Questionnaire (FFQ). The FFQ is the most common dietary assessment tool used in large epidemiologic studies of diet and health, and validated for the Polish population. It is an advanced tool that enables the evaluation of frequency (times/person/day) and amount (g/person/day) of food consumed during a year. The frequency of product consumption is determined by respondents: by free pointing to habitual intake frequency, during a defined period of time, from a list of 55 line items where each line item is defined by a series of foods or beverages.

**Sample collection and storage**

Fasting blood samples from all subjects were collected into tubes without anticoagulant, kept at room temperature for 30 minutes for clotting, and centrifuged at 3000 × g for 15 minutes at 4°C. After centrifugation, the serum samples were immediately frozen and stored in aliquots at –80°C until the analysis.

**Sample preparation and fatty acid methyl ester analysis**

Total lipids were extracted from serum using the method described by Folch et al. Obtained fatty acids were derivatized to fatty acid methyl esters (FAMEs) and analyzed, as previously described. In brief, total lipids were extracted from serum in a chloroform–methanol mixture (2:1, v/v). After drying, each sample of lipid extracts was hydrolyzed with 1 ml of 0.5 M KOH in methanol at 90°C for 3 hours. The mixture was acidified with 0.2 ml of 6 M HCl, and then 1 ml of water was added. Nonesterified fatty acids were extracted with 1 ml of n-hexane and evaporated to dryness in a stream of nitrogen. FAMEs were prepared using 1 ml of 10% boron trifluoride-methanol solution at 55°C for 90 minutes. Next, FAMEs were extracted with 1 ml of n-hexane, and the solvent was evaporated. FAMEs were analyzed by gas chromatography–mass spectrometry (GC-MS QP-2010 SE, Shimadzu Corporation, Kyoto, Japan). They were separated on a 30 m, 0.25 mm i.d., Rtx-5MS capillary column (film thickness, 0.25 μm). The column temperature was programed from 60°C to 300°C at a rate of 4°C/min with helium as the carrier gas.
**TABLE 1** Selected biochemical and anthropometric characteristics of the study groups

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Controls</th>
<th>CKD stage</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>1–2</td>
<td>3a</td>
</tr>
<tr>
<td>Age, y</td>
<td>56.00 (1.28)</td>
<td>53.65 (2.29)</td>
</tr>
<tr>
<td>Hemoglobin, g/dl</td>
<td>14.40 (0.19)</td>
<td>14.23 (0.21)</td>
</tr>
<tr>
<td>Creatinine, mg/dl</td>
<td>0.85 (0.03)</td>
<td>0.83 (0.03)</td>
</tr>
<tr>
<td>GFR, ml/min/1.73 m²</td>
<td>88.4 (2.22)</td>
<td>88.4 (2.47)</td>
</tr>
<tr>
<td>BUN, mmol/l</td>
<td>16.09 (0.66)</td>
<td>16.49 (0.64)</td>
</tr>
<tr>
<td>Triglycerides, mg/dl</td>
<td>131.10 (8.33)</td>
<td>121.28 (7.32)</td>
</tr>
<tr>
<td>Total cholesterol, mg/dl</td>
<td>211.28 (8.33)</td>
<td>212.95 (7.32)</td>
</tr>
<tr>
<td>HDL-C, mg/dl</td>
<td>131.17 (7.54)</td>
<td>126.29 (6.28)</td>
</tr>
<tr>
<td>hs-CRP, mg/l</td>
<td>2.82 (0.92)</td>
<td>3.38 (0.65)</td>
</tr>
<tr>
<td>Albumin, g/l</td>
<td>39.52 (0.45)</td>
<td>38.70 (1.06)</td>
</tr>
<tr>
<td>Glucose, mg/dl</td>
<td>102.48 (4.45)</td>
<td>102.67 (4.79)</td>
</tr>
<tr>
<td>Insulin, µU/ml</td>
<td>11.90 (0.97)</td>
<td>12.99 (1.17)</td>
</tr>
<tr>
<td>Na⁺, mmol/l</td>
<td>140.38 (0.41)</td>
<td>140.00 (0.41)</td>
</tr>
<tr>
<td>K⁺, mmol/l</td>
<td>4.36 (0.05)</td>
<td>4.24 (0.05)</td>
</tr>
<tr>
<td>BMI, kg/m²</td>
<td>27.34 (0.73)</td>
<td>27.52 (0.84)</td>
</tr>
<tr>
<td>HOMA</td>
<td>3.15 (0.41)</td>
<td>3.46 (0.38)</td>
</tr>
<tr>
<td>Concomitant diseases, n (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>3.33 (3.33)</td>
<td>12.50 (5.30)</td>
</tr>
<tr>
<td>Cardiovascular disease</td>
<td>3.33 (3.33)</td>
<td>15.00 (5.72)</td>
</tr>
<tr>
<td>Hypertension</td>
<td>33.33 (8.60)</td>
<td>70.00 (7.34)</td>
</tr>
</tbody>
</table>

Data are presented as mean (SD).

a Significant difference compared with healthy controls at P < 0.05

b Significant difference compared with healthy controls at P < 0.01

SI conversion factors: to convert glucose to mmol/l, multiply by 0.0555; total cholesterol, LDL-C, and HDL-C to mmol/l, multiply by 0.0259; and triglycerides to mmol/l, by 0.0113.

Abbreviations: BMI, body mass index; BUN, blood urea nitrogen; CKD, chronic kidney disease; GFR, glomerular filtration rate; HD, hemodialysis; HDL-C, high-density lipoprotein cholesterol; HOMA, Homeostatic Model Assessment; hs-CRP, high-sensitivity C-reactive protein; K⁺, potassium; LDL-C, low-density lipoprotein cholesterol; Na⁺, sodium; NT, not tested; PD, peritoneal dialysis; Tx, transplantation.

Statistical analysis  Statistical analyses were performed with SigmaPlot software (Systat Software, Inc., San Jose, California, United States). The intergroup differences were verified by 1-way analysis of variance, followed by an appropriate post hoc test. The univariate and multivariate regression tests were used to examine the correlations between selected variables. The diagnostic ability of selected parameters to predict CVD was examined, based on the receiver operating characteristic (ROC) curve analysis. A P value of less than 0.05 was considered significant for all analyses.

RESULTS  Laboratory and selected anthropometric parameters of all 207 participants were presented in Table 1. We detected 8 MUFA s in the examined serum samples. The mean (SD) total MUFA content increased with CKD progression. It was 29.6% (0.6%) in controls, 29.6% (0.9%) in CKD stage 1–2, 30.2% (0.7%) in CKD stage 3a, 31.4% (0.7%) in CKD stage 3b, 32.2% (0.5%) in CKD stage 4–5, 33.2% (1.0%) in HD patients, and 33.6% (0.9%) in PD patients (P < 0.05). In Tx recipients, it was slightly lower than in CKD stage 4–5 (mean [SD], 31.7% [0.7%]) (Table 2), although
TABLE 2  Content (% of total fatty acids) of the main classes of fatty acids in the serum of patients at subsequent stages of chronic kidney disease

<table>
<thead>
<tr>
<th>Fatty acids</th>
<th>Controls</th>
<th>CKD stage</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>1–2</td>
<td>3a</td>
</tr>
<tr>
<td>14:1, %</td>
<td>0.07 (0.01)</td>
<td>0.07 (0.01)</td>
</tr>
<tr>
<td>16:1, %</td>
<td>3.04 (0.17)</td>
<td>3.01 (0.12)</td>
</tr>
<tr>
<td>18:1, %</td>
<td>26.04 (0.55)</td>
<td>26.04 (0.47)</td>
</tr>
<tr>
<td>19:1, %</td>
<td>0.02 (0.002)</td>
<td>0.02 (0.002)</td>
</tr>
<tr>
<td>20:1, %</td>
<td>0.16 (0.01)</td>
<td>0.18 (0.01)</td>
</tr>
<tr>
<td>22:1, %</td>
<td>0.06 (0.004)</td>
<td>0.05 (0.004)</td>
</tr>
<tr>
<td>24:1, %</td>
<td>0.22 (0.01)</td>
<td>0.22 (0.01)</td>
</tr>
<tr>
<td>Total MUFA, %</td>
<td>31.67 (0.73)*</td>
<td>31.67 (0.73)*</td>
</tr>
<tr>
<td>Total SFA, %</td>
<td>33.12 (0.35)</td>
<td>33.44 (0.35)</td>
</tr>
<tr>
<td>Total n-6 PUFA, %</td>
<td>29.61 (0.95)*</td>
<td>28.51 (0.95)*</td>
</tr>
<tr>
<td>DI (18:1/18:0)</td>
<td>3.65 (0.12)</td>
<td>3.68 (0.10)</td>
</tr>
<tr>
<td>16:1/16:0</td>
<td>0.13 (0.007)</td>
<td>0.13 (0.004)</td>
</tr>
</tbody>
</table>

Data are presented as mean (SD).

a Significant difference compared with healthy control at P < 0.05

b Significant difference compared with healthy control at P < 0.01

Abbreviations: DI, desaturation index; MUFA, monounsaturated fatty acids; n-3 PUFA, omega-3 polyunsaturated fatty acids; n-6 PUFA, omega-6 polyunsaturated fatty acid; SFA, saturated fatty acids; others, see Table 1.

Other, indirect, factors of cardiovascular risk in CKD, albumin and hemoglobin levels, were negatively correlated with the serum MUFA level (r = −0.28, P < 0.01; r = −0.20, P < 0.01; respectively), while glucose levels showed a positive correlation (r = 0.215, P < 0.01) (Supplementary material, Table S1, Figure S1A–S1C). MUFA levels were strongly associated with the 18:1/18:0 SCD1 DI (r = 0.79, P < 0.01) (Supplementary material, Table S1). In a multiple regression model, CKD remained an independent predictor of MUFA levels after adjustment for age, sex, and comorbidities (P < 0.01).

Apart from the correlation between CKD stage and increased MUFA levels, we also observed a trend for a strong positive correlation between the CKD stage and the percentage of patients with CVD (r = 0.88, P < 0.01; Figure 2). Tx recipients were not included in this analysis because advanced CVD is a contraindication to kidney Tx, introducing a potential selection bias to the evaluation. To assess if MUFA may be added to currently known predictors of CVD, we performed the ROC curve analysis for potential predictors of CVD in CKD patients. As presented in Table 3, MUFA levels, together with age, creatinine, eGFR, BUN, LDL-C, albumin, and hemoglobin levels, were the strongest predictors of CVD in CKD patients (P < 0.01).

In order to examine if diet or endogenous MUFA synthesis contributes to an increase in serum MUFA levels in CKD patients, we analyzed their dietary intake as well as serum DI, defined as the ratio of fatty acids 18:1 to 18:0. DI is used to estimate the activity of SCD1 in...
DI showed a higher correlation with hs-CRP ($r = 0.19$, $P < 0.01$) (Supplementary material, Table S1). Serum DI as a measure of SCD1 activity in liver and adipose tissues at subsequent stages of CKD is presented in FIGURE 3. DI increased with CKD progression and was the highest in dialysis patients. In contrast, in every group of CKD lipogenic tissues. Similarly to serum MUFA levels, it was positively correlated with markers of CKD (creatinine and BUN) and serum TAG concentrations (Supplementary material, Table S1). A strong negative correlation between DI and serum HDL-C levels was observed ($r = -0.42$, $P < 0.001$). However, in comparison to MUFA,
There are numerous risk factors for development and progression of CVD in CKD patients. These factors are typically divided into 2 groups: traditional and nontraditional. The first group includes dyslipidemia, arterial hypertension, and obesity, while the second one, chronic inflammation, malnutrition, anemia, oxidative stress, and insulin resistance. Increased MUFA content seems to be associated with both these groups.

Dyslipidemia, characterized by abnormal levels of HDL-C and TAGs, is a common complication of CKD. Hypertriglyceridemia is a recognized risk factor for CVD in the general population. It was also reported that it might increase cardiovascular mortality in patients with CKD. Moreover, as CKD progression is associated with the development of hypertriglyceridemia, it is also possible that high TAG concentrations themselves contribute to CKD. One of the reasons for increased TAG in CKD patients may be decreased serum levels of irisin that reduces lipid synthesis in the liver. Our results suggest that the elevated TAG levels could, at least in part, be a consequence of the increased content of endogenous MUFAs. Since the SCD1, the rate-limiting enzyme in the biosynthesis of MUFAs, is closely colocalized to diacylglycerol acyltransferase-2 in the endoplasmic reticulum membrane, it is supposed that endogenously synthesized MUFAs are the main substrates for the synthesis of hepatocellular TAGs. It was reported that the SCD1 overexpression leads to hypertriglyceridemia. This is supported by the strong correlations between serum TAG, MUFA, and 18:1/18:0 DI found in our patients. On the other hand, the increase in serum MUFA levels in CKD patients may be also considered as reflecting increased TAG levels. Anyway, increased MUFA levels can be added to the list of lipid alterations characteristic for CKD.

DISCUSSION  Serum monounsaturated fatty acid content is associated with cardiovascular risk and inflammation in cardiovascular disease  The major finding of the present study is the positive correlation between the increased prevalence of CVD and serum MUFA content with subsequent CKD stages, as well as significant correlations between serum MUFA content and various markers or risk factors of CVD. CVD has enormous clinical importance in the course of CKD because cardiovascular mortality in CKD patients is several times higher compared with the general population. There are numerous risk factors for development and progression of CVD in CKD patients. These factors are typically divided into 2 groups: traditional and nontraditional. The first group includes dyslipidemia, arterial hypertension, and obesity, while the second one, chronic inflammation, malnutrition, anemia, oxidative stress, and insulin resistance. Increased MUFA content seems to be associated with both these groups.

Dyslipidemia, characterized by abnormal levels of HDL-C and TAGs, is a common complication of CKD. Hypertriglyceridemia is a recognized risk factor for CVD in the general population. It was also reported that it might increase cardiovascular mortality in patients with CKD. Moreover, as CKD progression is associated with the development of hypertriglyceridemia, it is also possible that high TAG concentrations themselves contribute to CKD. One of the reasons for increased TAG in CKD patients may be decreased serum levels of irisin that reduces lipid synthesis in the liver. Our results suggest that the elevated TAG levels could, at least in part, be a consequence of the increased content of endogenous MUFAs. Since the SCD1, the rate-limiting enzyme in the biosynthesis of MUFAs, is closely colocalized to diacylglycerol acyltransferase-2 in the endoplasmic reticulum membrane, it is supposed that endogenously synthesized MUFAs are the main substrates for the synthesis of hepatocellular TAGs. It was reported that the SCD1 overexpression leads to hypertriglyceridemia. This is supported by the strong correlations between serum TAG, MUFA, and 18:1/18:0 DI found in our patients. On the other hand, the increase in serum MUFA levels in CKD patients may be also considered as reflecting increased TAG levels. Anyway, increased MUFA levels can be added to the list of lipid alterations characteristic for CKD.

Chronic low-grade inflammation represents another typical complication in patients with CKD. Concurrent infections, comorbidities, uremia, and dialysis procedure in end-stage renal disease...
play an important role in the pathogenesis of an inflammatory state in the course of CKD. It is currently widely acknowledged that inflammation significantly contributes to atherosclerotic progression and to CVD risk in the general population. In CKD patients, a similar association has been documented. The major mechanisms include endothelial dysfunction and vascular calcification.

One of the most acknowledged inflammatory biomarkers is hs-CRP. Numerous studies have shown its strong relationship with cardiovascular outcome, both in the general population and in CKD patients. In the present study, a gradual increase in hs-CRP levels was observed across the CKD stages, reaching the highest values in patients on dialysis. The association between SCD1 index and inflammation was previously suggested by Petersson et al. In HD patients, some authors observed that estimated SCD1 activity was positively linked to inflammation, both in liver and adipose tissue. Inhibition of SCD1 modulates cellular inflammation and stress in different cell types and tissues including adipocytes, β cells, macrophages, as well as liver, aorta, skin, myocyte, and endothelial cells.

In our study, the correlation between MUFA, DI, and hs-CRP was significant, but weak. A much stronger association was observed between the MUFA content and the low albumin concentration. This is interesting because, in CKD patients, albumin is thought to reflect not only the nutritional status but also the chronic inflammatory state. Indeed, MUFAs were associated with low albumin levels despite a significant correlation with increasing body mass index, suggesting that decreased albumin concentrations were related to chronic inflammation rather than to poor nutritional status. According to some authors, low albumin levels are an even more potent risk factor for CVD than hs-CRP in CKD patients.

We previously documented strong associations between MUFAs and an inflammatory state in other patient groups. In the present study, significant links between MUFAs and inflammation indicate yet another mechanism behind the relationship of MUFA with CVD in CKD patients. The ROC curve analysis of our results showed that serum MUFA levels are among the most significant predictors of CVD in CKD. Thus, our results suggest that the elevation of serum MUFA levels might significantly contribute to CVD risk in this patient group.

Increased serum levels of monounsaturated fatty acids in chronic kidney disease patients are related to elevated endogenous synthesis rather than diet modifications. It is important to define the major mechanisms leading to an increase in MUFA levels during CKD. To solve this problem, we estimated the activity of SCD1 during CKD progression and assessed the consumption of MUFA-rich food products. The highest SCD1 activity is present in liver and adipose tissue. The increased activity is implicated in various disorders, including diabetes, obesity, and atherosclerosis. According to some authors, SCD1 activity in liver and adipose tissue is an independent predictive factor of mortality in dialysis patients. Since liver or adipose tissue were not available in our study, we estimated SCD1 activity indirectly by calculating 18:1/18:0 DI. DI presented a similar pattern of changes at subsequent stages of CKD as MUFAs (Table 2). In addition, it showed a strong correlation with MUFAs themselves (Supplementary material, Table S1). These results suggest that endogenous MUFA synthesis is the key determinant of serum MUFA levels.

The major exogenous MUFA sources include vegetable oils, high-fat fruits such as olives and avocados, red meat, whole milk products, and nuts. In some countries, consumption of MUFA accounts for as much as one-third of the total fat acid intake. Therefore, to investigate the impact of dietary MUFAs on the changes in serum MUFA levels during CKD progression, the dietary questionnaires of all participants were evaluated. Surprisingly, despite increased serum MUFA levels, the consumption of all MUFA-rich products was lower in CKD patients than in controls (Supplementary material, Table S2). Moreover, the results did not show significant correlations between the consumption of MUFA-rich food...
products and serum MUFA content in CKD patients. These results indicate that the increase in serum MUFA levels in CKD patients is not due to diet but rather results from increased endogenous synthesis by SCD1.

Our results are in contrast to a previous study by Huang et al. in Swedish CKD patients. However, those authors adopted a different approach to determine liver and adipose tissue SCD1 activity based on serum fatty acid composition in dialysis patients. Firstly, they estimated SCD1 activity by calculating 16:1/16:0 DI, since the diet of the Swedish population is rich in oleate that could have impacted the results. Secondly, they estimated liver SCD1 based on fatty acid content in serum phospholipids, and the adipose tissue SCD1 activity based on serum free fatty acid profiles. We did not find significant differences in 16:1/16:0 DI in study groups; however, stearic acid is a preferred SCD1 substrate, and the main product of liver desaturation is oleic acid, which is included in TAGs released from the liver into the blood. Moreover, CKD-related changes among MUFA were most pronounced in the case of oleic acid. Thus, considering that the serum TAG level is tightly associated with liver SCD1 activity in our study, we determined 18:1/18:0 DI in total serum lipids. The differences in the approach between our study and that by Huang et al. could explain the discrepancies in the results and the fact that, in contrast to Huang et al., we observed significant associations between serum DI and TAG, HDL-C, and other CVD risk factors.

Our results, suggesting an association between serum MUFA levels and increased risk of CVD in CKD patients, are also in contrast to studies analyzing the effects of dietary MUFA on human health, showing the potential of MUFA to reduce the CVD risk. The use of dietary MUFA reduced blood pressure and modulated the functions of immune system cells in animals. Finucane et al. emphasized that dietary MUFA intake, in contrast to saturated fatty acids, increases insulin sensitivity but also reverses disorders of adipose tissue function. The mechanisms of CVD risk reduction with dietary MUFA are still uncertain but include a simultaneous decrease in saturated fatty acid intake, a decrease in SCD1 activity, or both. However, in our study, the increased CVD risk seems to be associated with increased endogenous MUFA levels resulting from increased SCD1 activity, whereas the consumption of dietary MUFA was shown to be reduced in CKD patients. Paradoxically, since dietary MUFA inhibit the activity of SCD1, the increased consumption of MUFA could prevent the negative effect of increased SCD1 activity in CKD.

Our study has several limitations. First, it was a cross-sectional study, and as such cannot infer causality. Second, the studied cohort was relatively small. However, even with these sample size, the reported associations are strong and convincing. So far, research has focused mostly on the role of omega-3 PUFAs in CKD patients. Our study is novel in that it showed that MUFA can also play an important role in the development of CKD complications.

In conclusion, the present work documents a gradual increase in serum MUFA content across the consecutive stages of CKD. Our results suggest that the major mechanism responsible for increased MUFA content is enhanced endogenous synthesis through the increased activity of SCD1, rather than the effect of dietary MUFA intake. Furthermore, the study demonstrates associations linking increased MUFA content and SCD1 activity with markers of cardiovascular risk and with CVD itself. The measurement of MUFA derived from endogenous SCD1 activity can be a useful marker of CVD risk and perhaps even a target for therapeutic interventions.

SUPPLEMENTARY MATERIAL

Supplementary material is available with the article at www.pamw.pl.

ACKNOWLEDGMENTS This study was supported by the National Science Centre Poland (grant no. NCN 2013/11/B/NZ5/00118; to MC) and was supported by the Ministry of Science and Higher Education of the Republic of Poland (DS 530-8615-D690-17; to PS), and Medical University of Gdansk (grants no. ST40 [to TS], ST4 [to AD-Ś]).

CONTRIBUTION STATEMENT MS-W and MC collected research material and analyzed clinical data; AM, MC, and TS designed the research; AM and SM performed the research; AM, PS, AD-Ś, and TS analyzed data; AM, MC, and TS wrote the paper. All authors read and approved the final manuscript.

OPEN ACCESS This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License (CC BY-NC-SA 4.0), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited, distributed under the same license, and used for non-commercial purposes only. For commercial use, please contact the journal office at pamw@mp.pl.

REFERENCES

tients: differences in clinical characteristics and predictors of 1-year out-
come in the Polish ESC-HF Long-Term Registry. Pol Arch Med Wewn. 2016;
126: 502-513.
omega-3 fatty acid composition in dialyzed patients, and their associations
8. Huang X, Stenvinkel P, Gareisi AR, et al. Clinical determinants and mor-
tality predictability of stearoyl-CoA desaturase 1 activity indices in dialysis
9. Liu X, Strable MS, Ntambi JM. Stearoyl CoA desaturase 1: role in cel-
10. Huang X, Lindholm B, Stenvinkel P, Carrero JJ. Dietary fat modifica-
tion in patients with chronic kidney disease: n-3 fatty acids and beyond.
12. Mika A, Sledzinski T. Alterations of specific lipid groups in serum of
13. Srivardhanuwat N, Kupahana NS, Cekanova M, et al. Modulation of ad-
ipose tissue inflammation by bioactive food compounds. J Nutr Biochem. 2013;
24: 613-623.
15. Hammad S, Pu S, Jones PJ. Current evidence supporting the link be-
tween dietary fatty acids and cardiovascular disease. Lipids. 2016; 51:
507-517.
16. Degiolamo C, Rudel LL. Dietary monounsaturated fatty acids appear-
17. Mika A, Kaska L, Kozyczewska J, et al. Visceral and subcutaneous adi-
pose tissue stearoyl-CoA desaturase-1 mRNA levels and fatty acid desatu-
ration index positively correlate with BMI in morbidly obese women. Eur J
cific fatty acids of serum lipids and serum high sensitivity C-reactive pro-
tein levels in morbidly obese women. Cell Physiol Biochem. 2014; 34:
1101-1108.
food frequency questionnaire with the three-day unweighted food records in
5: 2747-2776.
21. Fölich J, Lees M, Sleane Stanley GH. A simple method for the isola-
tion and purification of total lipides from animal tissues. J Biol Chem. 1957;
226: 497-509.
32. Sledzinski T, Mika A, Stepnowski P, et al. Identification of cyclopro-
panoecanonic acid 2-hexyl in human adipose tissue and serum. Lipids. 2013;
48: 839-848.
33. Yao Q, Peczoks-Filo R, Lindholm B, Stenvinkel P. Traditional and non-
traditional risk factors as contributors to atherosclerotic cardiovascular
disease in end-stage renal disease. Scand J Urol Nephrol. 2004; 38:
405-416.
35. Jacobsson TA, Maki KC, Oringer CE, et al; on behalf of the NLA Ex-
pert Panel. National Lipid Association recommendations for patient-centered
36. Navaneethan SD, Schild JD, Arigiani S, et al. Serum triglycerides and
risk for death in Stage 3 and Stage 4 chronic kidney disease. Nephrol Dial
37. Shimizu M, Furuyu N, Mitsuomoto F, et al. Subclinical carotid athero-
 sclerosis and triglycerides predict the incidence of chronic kidney disease in
the Japanese general population: results from the Kyushu and Okinawa Pop-
ulation Study (KOPS). Atherosclerosis. 2015; 238: 207-212.
the protective effect of hepatic steatosis in vitro. Cell Signal. 2015; 27:
1831-1839.
39. Ebert T, Kralisch S. Newly discovered myokines in chronic kidney dis-
via stearoyl-CoA desaturase-1 are endogenous inhibitors of fatty acid amide
41. Jayakumar SM, Lopamudra P, Padmini S, et al. Fatty acid desatura-
tion index correlates with body mass and adiposity indices of obesity in Wi-
star NPI obese mutant rat strains WINN/Ob and WINN/GR-Ob. Nutr Metab
42. Honda H, Ouzeshi AR, Heimburger O, et al. Serum albumin, C-reactive
protein, interleukin 6, and fetuin A as predictors of malnutrition, cardiovas-
cular disease, and mortality in patients with ESRD. Am J Kidney Dis. 2006;
47: 139-148.